An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Saama Appoints Scott Rogers as Company’s Chief Financial Officer
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Saama Technologies has appointed Scott Rogers as the new Chief Financial Officer, effective January 31, 2022. Rogers brings 17 years of industry experience, previously serving as Senior Vice President of Clinical Finance at PPD, where he oversaw clinical development finance. This appointment follows a significant $430 million growth investment by Carlyle and venture funds from leading biopharma firms. Saama aims to leverage Rogers’ expertise in finance and clinical development to strengthen its position in the AI-driven life sciences sector.
Positive
Scott Rogers brings extensive financial and clinical experience beneficial for Saama's growth.
Appointment follows a significant $430 million growth investment, signaling confidence in Saama's future.
Negative
Scott Rogers may face challenges in adapting to Saama's corporate culture and existing team dynamics.
Scott brings a unique combination of financial and clinical fused with growth experience to Saama
New CFO appointment follows October announcement of $430M growth investment
CAMPBELL, Calif.--(BUSINESS WIRE)--
Saama Technologies, Inc. (“Saama”) today announced that Scott Rogers, 17-year industry veteran, has been appointed as the company’s Chief Financial Officer, effective January 31, 2022. In this position Scott is responsible for leading the company’s global finance organization and will report to Saama Founder and CEO Suresh Katta.
Scott comes to Saama with significant financial executive experience in clinical development, commercial growth, and financial reporting and compliance. He progressed rapidly through the industry, and most recently served as Senior Vice President of Clinical Finance at Pharmaceutical Product Development (PPD, Inc.; Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industries. In that role Scott oversaw a portfolio of the contract research organization’s businesses across the phases of clinical development. He also had direct responsibility for PPD’s adjunct business units, including consulting, digital and enrollment solutions, where he worked to optimize business performance and communicate to executives and owners. While at PPD, Scott also implemented a global leadership program designed to enhance the career development and engagement of the finance team.
“We are very excited to have Scott join the dynamic Saama leadership team as CFO, a key position for Saama following our recent $430 million growth investment by Carlyle and the venture fund arms of leading biopharma companies,” said Suresh Katta. “Scott is a high-impact executive who brings a compelling blend of financial experience and deep understanding of clinical development that accelerates Saama’s journey towards establishing ClinTech Category leadership in the drug development industry.”
“I am honored to be appointed as Saama’s CFO at such an exciting juncture in the company’s history after their milestone growth investment,” said Scott. “I am passionate about using the language of finance to enhance Saama’s performance and help tell the story of how industry is embracing AI technologies to accelerate the delivery of safe and effective medical treatments.”
Scott began his career at PricewaterhouseCoopers as an auditor, then moved into corporate finance in the pharmaceutical industry. Scott holds an accounting degree from Texas Tech University and is a Certified Public Accountant.
About Saama Technologies, Inc.
Saama is the #1 AI-driven Intelligent Clinical Cloud company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs. Today, over 50 biotech companies use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform on more than 1,500 studies, including many of the top 20 pharmaceutical companies. LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster. Discover more at www.saama.com and follow Saama @SaamaTechInc.
